Mark Alan Goldberg is EVP & Medical & Reg. Strategy at SYNAGEVA BIOPHARMA CORP (GEVA). They have made 12 open-market trades across 4 companies since 2012, most recently 2025-07-17.
CIK 0001532475
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $624K since 2012, against 6 sales. Across 6 scored buys the stock is up 19.8% at ninety days, and 16.1 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 17% | 33% | 50% |
| Avg Move | -7.3% | +6.7% | +19.8% |
| Alpha | -6.7% | +4.8% | +16.1% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BPMC | BUY | 2022-03-03 | 2022-03-07 | $59.98 | $300K | +15.5% | +28.5% | +6.5% |
| BPMC | SELL | 2020-12-24 | 2020-12-28 | $125.00 | $682K | -11.8% | -26.1% | -25.0% |
| BPMC | SELL | 2020-12-18 | 2020-12-22 | $120.00 | $654K | -18.0% | -19.9% | -15.8% |
| BPMC | SELL | 2020-12-11 | 2020-12-15 | $115.00 | $627K | +4.2% | -12.8% | -10.0% |
| BPMC | SELL | 2020-12-01 | 2020-12-03 | $110.00 | $600K | +17.4% | +3.7% | -7.7% |
| BPMC | SELL | 2020-10-19 | 2020-10-21 | $105.00 | $573K | -1.8% | -2.6% | +2.1% |
| BPMC | SELL | 2020-10-07 | 2020-10-09 | $100.00 | $545K | -0.3% | -1.3% | +6.3% |
| IDRA | BUY | 2018-12-19 | 2018-12-20 | $3.19 | $32K | -7.4% | -19.2% | -7.1% |
| IMGN | BUY | 2018-11-06 | 2018-11-07 | $5.76 | $173K | -9.2% | -12.5% | -20.8% |
| IMGN | BUY | 2016-12-15 | 2016-12-15 | $1.80 | $36K | -5.3% | +49.7% | +119.9% |
| GLYC | BUY | 2016-03-04 | 2016-03-07 | $4.77 | $50K | -7.8% | -3.1% | +23.5% |
| GEVA | SELL · 10b5-1 | 2014-09-19 | 2014-09-19 | $65.24 | $52K | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2014-09-16 | 2014-09-18 | $65.03 | $883K | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2014-06-11 | 2014-06-12 | $80.00 | $1.7M | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2013-12-03 | 2013-12-04 | $60.52 | $424K | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2013-11-01 | 2013-11-04 | $49.96 | $350K | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2013-10-01 | 2013-10-03 | $64.31 | $450K | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2013-04-01 | 2013-04-03 | $54.31 | $240K | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2013-03-01 | 2013-03-06 | $50.76 | $224K | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2013-02-01 | 2013-02-05 | $47.75 | $211K | N/A | N/A | N/A |
| GEVA | SELL · 10b5-1 | 2013-01-02 | 2013-01-04 | $47.52 | $210K | N/A | N/A | N/A |
| IMGN | BUY | 2012-11-08 | 2012-11-09 | $11.27 | $34K | -29.5% | -3.5% | -3.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.